ArticleBreast cancer research and treatment2022
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999-2018.
Henry G Kaplan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this paperpooled itcites it